1、 TERZOUDIS S, MALLIARAKI N, DAMILAKIS J, et al. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease[J]. Eur J GastroenterolHepatol, 2016,28(7):814-819. TERZOUDIS S, MALLIARAKI N, DAMILAKIS J, et al. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease[J]. Eur J GastroenterolHepatol, 2016,28(7):814-819.
2、 CAMPOS PASTOR M M, LOPEZ-IBARRA PJ, ESCOBAR-JIMENEZ F,et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study[J]. Osteoporos Int,2000,11(5):455-459. CAMPOS PASTOR M M, LOPEZ-IBARRA PJ, ESCOBAR-JIMENEZ F,et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study[J]. Osteoporos Int,2000,11(5):455-459.
3、 CARNEVALE V, ROMAGNOLI E, D'ERASMO L, et al.Bone damage in type 2 diabetes mellitus[J]. Nutr Metab Cardiovasc Dis,2014,24(11):1151-1157. CARNEVALE V, ROMAGNOLI E, D'ERASMO L, et al.Bone damage in type 2 diabetes mellitus[J]. Nutr Metab Cardiovasc Dis,2014,24(11):1151-1157.
4、 MELTON L J, LEIBSON C L, ACHENBACH S J, et al. Fracture risk in type 2 diabetes: update of a population-based study[J]. J Bone Miner Res,2008,23(8):1334-1342. MELTON L J, LEIBSON C L, ACHENBACH S J, et al. Fracture risk in type 2 diabetes: update of a population-based study[J]. J Bone Miner Res,2008,23(8):1334-1342.
5、 GILBERT M P,PRATLEY R E. Theimpact of diabetes and diabetes medications on bone health[J]. Endocrine Rev,2015,36(2):194-213. GILBERT M P,PRATLEY R E. Theimpact of diabetes and diabetes medications on bone health[J]. Endocrine Rev,2015,36(2):194-213.
6、 KAUR J, ADYA R, TAN B K, et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis[J]. Biochem Biophys Res Commun,2010,391(4):1762-1768. KAUR J, ADYA R, TAN B K, et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis[J]. Biochem Biophys Res Commun,2010,391(4):1762-1768.
7、 CHEW E Y, KLEIN M L, FERRIS F L, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22[J]. Arch Ophthalmol,1996,114(9):1079-1084. CHEW E Y, KLEIN M L, FERRIS F L, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22[J]. Arch Ophthalmol,1996,114(9):1079-1084.
8、 ROH S G,SONG S H,CHOI K C,et al. Chemerin——a new adipokine that modulates adipogenesis via its own receptor[J]. Biochem Biophys Res Commun, 2007,36(4):1013-1018. ROH S G,SONG S H,CHOI K C,et al. Chemerin——a new adipokine that modulates adipogenesis via its own receptor[J]. Biochem Biophys Res Commun, 2007,36(4):1013-1018.
9、 陈曾,徐展望,向亮,等.脂肪因子chemerin 与骨质疏松症的关系展望[J]. 中国骨质疏松杂,2015(2):231-234;240. 陈曾,徐展望,向亮,等.脂肪因子chemerin 与骨质疏松症的关系展望[J]. 中国骨质疏松杂,2015(2):231-234;240.
10、 LEIDIG-BRUCKNER G G,GROBHOLZ S,BRUCKNER T,et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus[J]. BMC Endocr Disord,2014,11:14-33. LEIDIG-BRUCKNER G G,GROBHOLZ S,BRUCKNER T,et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus[J]. BMC Endocr Disord,2014,11:14-33.
11、 NEGLIAC,AGNELLON,ARGENTIEROA,et al. Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements[J]. J Biol Regul Homeost Agents,2014,28(4):733-741. NEGLIAC,AGNELLON,ARGENTIEROA,et al. Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements[J]. J Biol Regul Homeost Agents,2014,28(4):733-741.
12、 TING D S, CHEUNG G C, WONG T Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J]. Clin Exp Ophthalmol, 2016,44(4):260-277. TING D S, CHEUNG G C, WONG T Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J]. Clin Exp Ophthalmol, 2016,44(4):260-277.
13、 徐瑜, 毕宇芳, 王卫庆, 等.中国成人糖尿病流行与控制现状—2010年中国慢病监测暨糖尿病专题调查报告解读[J]. 中华内分泌代谢杂志,2014,30(03):184-186. 徐瑜, 毕宇芳, 王卫庆, 等.中国成人糖尿病流行与控制现状—2010年中国慢病监测暨糖尿病专题调查报告解读[J]. 中华内分泌代谢杂志,2014,30(03):184-186.
14、 BOZAOGLU K, BOLTON K, MCMILLAN J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinology, 2007,148(10):4687-4694. BOZAOGLU K, BOLTON K, MCMILLAN J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinology, 2007,148(10):4687-4694.
15、 WAKI H,TONTONTONOZ P.Endocrine functions of adipose tissue[J]. Annu Rev Pathol, 2007(2):31-56. WAKI H,TONTONTONOZ P.Endocrine functions of adipose tissue[J]. Annu Rev Pathol, 2007(2):31-56.
16、 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志, 2014 (07):447-498. 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志, 2014 (07):447-498.